Dependence on Key Products: While Gilead Sciences Inc (NASDAQ:GILD) has a strong product lineup, its financial performance is ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

Gilead Sciences (GILD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after market close. Leerink ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...